HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rutkove, S. B. Articles by Raynor, E. M. Search for Related Content PubMed PubMed Citation Articles by Rutkove, S. B. Articles by Raynor, E. M. Related Collections Muscle disease Clinical trials Randomized controlled (CONSORT agreement)

A pilot randomized trial of oxandrolone in inclusion body myositis

From the Department of Neurology (Drs. Rutkove, Nardin, and Raynor), Beth Israel Deaconess Medical Center, Harvard Medical School, and Beth Israel Deaconess Biometrics Center (Dr. Parker and C. Connolly), Boston, MA; and Department of Neurology (Dr. Felice), University of Connecticut School of Medicine, Farmington.

Address correspondence and reprint requests to Dr. Seward B. Rutkove, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, TCC-810, Boston, MA 02215; e-mail: srutkove{at}caregroup.harvard.edu

Background: Inclusion body myositis (IBM) remains without effective therapy. As anabolic steroids have myotrophic properties, the authors studied whether a synthetic androgen, oxandrolone, would have efficacy in IBM.

Methods: A double-blind, placebo-controlled, crossover design was used. Patients received oxandrolone or placebo for 12 weeks followed by a minimum 2-month washout period, followed by 12 weeks of the alternative treatment. Maximal voluntary isometric contraction testing (MVICT), manual muscle testing (MMT), and functional performance testing were obtained before and after each treatment period, with the whole-body MVICT score as the primary outcome measure.

Results: Of 19 patients enrolled, 16 (14 men, 2 women; median age 68.5 years) had complete data for at least the first treatment period, with 13 completing the entire study. Whole-body MVICT improved by a median of 15.5 kg with drug and 4.1 kg with placebo (p = 0.06), whereas MMT demonstrated a median increase of 2.0 Medical Research Council points with drug and 0.9 point with placebo (p = 0.33). Upper-extremity MVICT demonstrated a significant treatment effect, with strength increasing a median 6.3 kg with drug vs 2.5 kg with placebo (p = 0.006). Stair climbing also increased a median of 1 step on average with drug versus no change with placebo (p < 0.001). Minimal adverse effects occurred.

Conclusions: Oxandrolone had a borderline significant effect in improving whole-body strength and a significant effect in improving upper-extremity strength as measured by MVICT. Given these findings, further study of this drug, possibly in combination with an immunomodulating agent, is warranted.

This article has been cited by other articles:

				A A Amato and R J Barohn Inclusion body myositis: old and new concepts J. Neurol. Neurosurg. Psychiatry, November 1, 2009; 80(11): 1186 - 1193. [Abstract] [Full Text] [PDF]

				S. A Greenberg How citation distortions create unfounded authority: analysis of a citation network BMJ, July 23, 2009; 339(jul20_3): b2680 - b2680. [Abstract] [Full Text] [PDF]

				M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model J. Neurosci., May 13, 2009; 29(19): 6132 - 6141. [Abstract] [Full Text] [PDF]

				R. C. Griggs The current status of treatment for inclusion-body myositis Neurology, January 24, 2006; 66(1_suppl_1): S30 - S32. [Abstract] [Full Text] [PDF]